NeurAegis is a preclinical stage neuropharmaceutical company pioneering the development of breakthrough treatments for neurological disorders. Founded in 2016, our initial focus is developing first-in-class, novel protease inhibitors for mild traumatic brain injury (concussion) where there are currently no FDA approved treatments.
NeurAegis Scientific Founder Michel Baudry Awarded $3.8M Grant from the Department of Defense to Advance Product Candidate for Treating Traumatic Brain Injury and Concussion
NeurAegis is led by a team with deep, relevant experience for developing novel therapeutics.
Michel Baudry, PhD
Founder & CSO
David Baron, DO
Chief Medical Officer
Mike Palfreyman, DSc. PhD
SVP, Drug Development